Shots:

• The MHLW has granted Chugai’s RG6042 an ODD for the expected treatment of Huntington's disease
• The RG6042 is currently being evaluated in P-III GENERATION HD1 study and is expected to delay the progression of Huntington’s disease as the first disease-modifying therapy
• RG6042 (ONIS-HTT_Rx) is an antisense oligonucleotide targeting HTT mRNA and has received FDA & EMA’s ODD for the Huntington's disease in May & Dec’2015 with EMA’s PRIME designation in 2018

Click here ­to­ read full press release/ article | Ref: Chugai | Image: Wikipedia